



PRESS RELEASE

23 July 2024 09:53:00 CEST

AcouSort to present at two prestigious conferences

AcouSort has been selected to present on the latest new developments in acoustic trapping and acoustic separations at two upcoming conferences – the Gordon Research Conference on Extracellular Vesicles and the Acoustofluidics 2024 conference.

The Gordon Research Conference is a premier, international scientific conference focusing on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. The conference program includes a diverse range of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in the field.

“The Gordon Research Conference is a fantastic opportunity for us to present our unique technology to leading scientists from around the world. The two posters that we present here will focus on how the AcouTrap system can improve nanoparticle isolation from various types of sample media. Our AcouTrap technology has the potential to enable early and effective diagnostics based on analyzing exosomes and extracellular vesicles extracted from body fluids,” says Agnes Michanek, Commercial Director at AcouSort.

The Acoustofluidics 2024 conference is dedicated to exploring the science, the engineering, and the use of micro and nanoscale acoustofluidics. The conference was first held in 2003 as part of a UK based network called USW net. Today, the conference has grown into an international event gathering researchers working with all different aspects of acoustofluidics and its applications within life sciences. At this conference, AcouSort has been selected to present its latest research both in an oral presentation and a poster presentation.

“The Acoustofluidics 2024 conference is a great place for us to meet outstanding scientist in our field and to share our knowledge, experience and research with them. The acoustofluidics technology still has many untapped opportunities, and meeting up with colleagues in the field is one way for AcouSort to expand long-term commercial opportunities”, says Agnes Michanek.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com



PRESS RELEASE

23 July 2024 09:53:00 CEST

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).